In a significant stride forward for genetic medicine, Prime Medicine has announced encouraging initial clinical data for PM359, the company’s prime-edited therapy targeting the p47phox variant of Chronic Granulomatous Disease (CGD). This marks a landmark achievement in the first human trial for CGD, a rare genetic disorder, and underlines the potential of Prime Medicine’s groundbreaking […]